Last edition
News about "actimed therapeutics"
Actimed Therapeutics Announces Licensing Agreement with Mankind Pharma
Actimed Therapeutics has entered into an exclusive licensing agreement with Mankind Pharma for S-pindolol, its novel therapy in development for cancer cachexia. The partnership marks a step toward delivering the first globally approved treatment for this debilitating condition to patients across India and South Asia.
Actimed Therapeutics | 21/11/2025 | By Dineshwori
Actimed Therapeutics receives S-pindolol patent in the UK
Actimed Therapeutics Ltd, a clinical stage company focused on bringing innovation to the treatment of muscle wasting disorders, announced the grant of a new UK Patent (GB 2593902 B) covering new salts of S-pindolol for use in the treatment or prevention of cachexia with an expiry date in 2040.
Actimed Therapeutics | 05/05/2022 | By Sudeep Soparkar | 1191
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy